辛伐他汀对急性冠状动脉综合症血脂及vWF因子的影响

目的：探讨辛伐他汀对早期急性冠状动脉综合症患者血浆及vWF水平的影响。方法：将120例性冠状动脉综合症患者随机分为常规治疗组（60例）与辛伐他汀治疗组（60例）,常规治疗组采用拜阿司匹林、硝酸酯类、血管紧张素转换酶抑制剂等,辛伐他汀组在常规治疗基础上加用辛伐他汀;疗程8周。检测患者治疗前后的hs-CRP、LDL-C、HDL-C、TC、TG与vWF等因子水平的变化。选取60例健康人作为对照组。结果：常规治疗组中患者的hs-CRP、TC与vWF的水平明显下降（P〈0.05）;辛伐他汀组中患者的hs-CRP、LDL-C、TC、TG与vWF的水平明显下降（P〈0.01）、而HDL-C的水平明显升高（P〈0.05）。与常规治疗组相比,辛伐他汀组中患者的hs-CRP、LDL-C、TG与vWF的的水平变化差异均有统计学意义（P〈0.05）。结论：常规药物联合辛伐他汀治疗早期急性冠状动脉综合症可获得较好的疗效。

Effects of administration of Simvastatin treatment on plasma levels ofvWF and blood fat on the Acute Coronary Syndromes

Objective： To investigate the therapeutic effect of the acute coronary syndromes with simvastatin. Methods： 120 acute coronary syndromes cases were randomly divided into two groups. There were sixty acute coronary syndromes cases in each group. Group Ⅰ was treated with the conventional therapy method （ Aspirin, nitrate, angiotensin converting enzyme inhibitor, and so on）. Group Ⅱ, based on the conventional therapy method, was treated with simvastatin. After eight weeks, the levels of the hs-CRP, TC,TG, LDL-C and HDL-C of the cases before and after treatment were detected. 60 healthy adults were considered as the control group. Results： After eight weeks of treatment, a significant degression was found for the level of the hs-CRP, TC and vWF of the cases in control group（P〈0. 05 ）. and obviously degression for the level of the hs-CRP, LDL-C, TC, TG and vWF of the cases in group Ⅱ （P〈0.05）, but the level of the HDL-C was significantly increased. Compared with the control group or the group Ⅰ, the level change of the hs-CRP, TG, LDL-C and vWFofthe cases in group Ⅱ has statistical significance, respectively （P〈0.05）. Conclusions： Simvastatin is a good medicine for the acute coronary syndromes, and simvastatin combined with common medicine could obtain more therapeutic efficacy.